A team from Peking Union Medical College led by Xue Zhang have uncovered a DNA mechanism which results in Maria Unna hereditary hypotrichosis (MUHH), a baldness that strikes before adulthood.
MUHH is a rare inherited condition characterized by hair loss that starts during childhood and it affects both men and women - children born with the condition have very little or no hair at birth and have wiry or coarse hair in childhood which they progressively lose at puberty.
Victims often have no eyebrows or eyelashes, very little armpit and pubic hair and poor nails and women often have normal thickness hair which does not grow very long and loss of hair on other parts of the body.
The culprit in MUHH are flaws in the gene U2HR located on Chromosome 8, which acts as a key switch in the process as it controls a small peptide that in turn affects a protein called the human hairless monolog, or HR, which is crucial for the regeneration of hair follicles.
The discovery was made by trawling through the genome of 19 Chinese families with a history of MUHH, which is how the team found that mutations of U2HR led to increased levels of HR.
The researchers say the death of the hair follicles increases the likelihood of this kind of baldness and they suggest their research may offer the potential for a new drug to block this pathway and treat baldness.
The Chinese team say that fine-tuning HR protein levels is important in control of hair growth, and they have found a potential mechanism for preventing hair loss or promoting hair removal.
The study is published online in the journal Nature Genetics.
"The discovery of these selective estrogen regulatory elements strengthens our SERM discovery engine," said Isaac Cohen, Bionovo's Chairman and Chief Executive Officer. "The advantage of the new array, of specific regulatory elements, is manifest in the pharmacological and toxicological insights gained. We can now acquire higher predictive value and greater specificity from a complex biological system such as the regulation of the estrogen receptor pathways. I believe this puts Bionovo at the forefront of future SERM products which are far more specific and a more favorable safety profile. This is a breakthrough for all future drugs that regulate the vast diverse effects of conditions affected by nuclear receptors. Bionovo is positioned to explore and exploit these pathways for many serious diseases with its expanded scientific collaborations. We are proud to continue pursuing our innovative approaches to drug discovery and development in these challenging times."
bionovo/